• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·NIKA
Share

NIKA PHARMACEUTICALS INC. Stocks

$ 0.77Last Updated 28.07.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 806.33M

$ 0.77
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 22:26

The Kazakh Market: CPC as a Risk Factor, the Summer Slowdown, and Weakening Support for the Tenge

31.07.2026 21:55

Roblox shares plummeted 30%. Analysts have begun advising investors to sell them

31.07.2026 21:48

Worst reaction to an earnings report in 13 years: Apple risks losing $460 billion in market value in a single day

31.07.2026 21:35

Three Fed officials said interest rates need to be raised to combat inflation

31.07.2026 20:36

Nvidia Finds Itself in the Unfamiliar Role of an Undervalued Growth Stock — Morningstar

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026